Cargando…
Does Weight Gain Associated with Thiazolidinedione Use Negatively Affect Cardiometabolic Health?
Thiazolidinediones (TZDs) are oral anti-diabetic drugs that are peroxisome proliferator-activated receptor gamma (PPARγ) agonists and act as insulin sensitizers. The clinical efficacy and durability of the currently available TZDs in improving glycemic control are well established. However, TZDs cau...
Autores principales: | Ko, Ki Dong, Kim, Kyoung Kon, Lee, Kyu Rae |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society for the Study of Obesity
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6484909/ https://www.ncbi.nlm.nih.gov/pubmed/31089503 http://dx.doi.org/10.7570/jomes.2017.26.2.102 |
Ejemplares similares
-
Weight gain in infancy and markers of cardiometabolic health in young adulthood
por: Nummela, Saga Rebecca, et al.
Publicado: (2022) -
Avoiding Weight Gain in Cardiometabolic Disease: A Systematic Review
por: Maruthur, Nisa M., et al.
Publicado: (2014) -
Novel thiazolidinedione analog reduces a negative impact on bone and mesenchymal stem cell properties in obese mice compared to classical thiazolidinediones
por: Benova, Andrea, et al.
Publicado: (2022) -
The impact of maternal gestational weight gain on cardiometabolic risk factors in children
por: Tam, Claudia H. T., et al.
Publicado: (2018) -
Chemotherapy and Chemoprevention by Thiazolidinediones
por: Fröhlich, Eleonore, et al.
Publicado: (2015)